Literature DB >> 10934342

Flow cytometric analysis of glycosylphosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size.

J Piedras1, X López-Karpovitch.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by total or partial deficiency of membrane proteins anchored to the cell surface through a glycosylphosphatidyl-inositol (GPI) moiety. The relationship between the size of the PNH clone, determined by the expression of GPI-anchored proteins (AP; CD14, CD48, CD55, CD59, and CD66b) on erythrocytes, lymphocytes, monocytes, and granulocytes using forward and side scatter analysis, and severity of the disease was evaluated in 19 PNH patients. CD55 antigen expression did not delineate abnormal erythrocytes as well as did anti-CD59. The proportion of monocytes deficient in CD55, CD59, CD48, and CD14 (48-97%) and of granulocytes deficient in CD55, CD59, and CD66b (60-99%) was greater than the proportion of erythrocytes deficient in CD59 (24-95%) and the proportion of lymphocytes deficient in CD55 and CD59 (30-98%). There were no significant correlations among reticulocyte, leukocyte, and platelet counts and GPI-AP-deficient immunophenotypes in red and white blood cells. However, high coefficients of determination were seen between hemoglobin levels and granulocytes deficient in CD59 (r(2) = 0.76), CD55 (r(2) = 0.74), and CD66b (r(2) = 0.74) antigens and between hemoglobin and monocytes deficient in CD55 (r(2) = 0.73), CD59 (r(2) = 0.80), and CD14 (r(2) = 0.75) antigens. These results are interpreted as indicating that the size of PNH clone is better assessed by immunophenotypic analysis of monocytes and granulocytes rather than of lymphocytes and erythrocytes. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934342     DOI: 10.1002/1097-0320(20000815)42:4<234::aid-cyto3>3.0.co;2-6

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  6 in total

1.  Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

Authors:  Phillip Scheinberg; Michael Marte; Olga Nunez; Neal S Young
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

2.  Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Weiqiang Gao; Zhaoyue Wang; Xia Bai; Yuyun Li; Changgeng Ruan
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 3.  Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances.

Authors:  Prabhu Manivannan; Ankur Ahuja; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2017-09-08       Impact factor: 0.900

4.  Paroxysmal nocturnal hemoglobinuria clone in 103 Brazilian patients: diagnosis and classification.

Authors:  Ana Paula de Azambuja; Mariester Malvezzi; Marco Antonio Bitencourt; Michel Michels Oliveira; Larissa Alessandra Medeiros; Ricardo Pasquini
Journal:  Rev Bras Hematol Hemoter       Date:  2015-01-30

5.  Value of CD16/CD66b/CD45 in comparison to CD55/CD59/CD45 in diagnosis of paroxysmal nocturnal haemoglobinuria: An Indian experience.

Authors:  Mrinalini Kotru; Rahul Sharma; Suman Kumar Pramanik; Abhishek Purohit; Gurmeet Singh; Avinash Kumar Singh; Deepti Muterja; Pravas Mishra; Tulika Seth; Seema Tyagi; Manoranjan Mahapatra; Hara Prasad Pati; Renu Saxena
Journal:  Indian J Med Res       Date:  2017-09       Impact factor: 2.375

6.  Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection.

Authors:  Alina E Dulau-Florea; Neal S Young; Irina Maric; Katherine R Calvo; Cynthia E Dunbar; Danielle M Townsley; Thomas Winkler; Mariela Monreal; Chunjie Jiang; Elaine K Jordan; Raul C Braylan
Journal:  Am J Clin Pathol       Date:  2018-07-31       Impact factor: 2.493

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.